title: [Effect of rosiglitazone on tumor necrosis factor-alpha-induced nuclear factor-kappaB and coupling factor 6 expressions in human umbilical vein endothelial cells].
abstract: OBJECTIVE
  To investigate the effect of rosiglitazone on the expression of nuclear factor-kappaB (NF-kappaB) and coupling factor 6 (CF6) induced by tumor necrosis factor-alpha (TNF-alpha) in cultured human umbilical vein endothelial cells (HUVEC).
  
  
  METHODS
  Cultured HUVEC of passage 3-5 were stimulated with TNF-alpha and then cultured in the presence of rosiglitazone. The expression of CF6 and NF-kappaB subunit p65 were evaluated by immunocytochemistical method.
  
  
  RESULTS
  Pretreatment of HUVECs with rosiglitazone inhibited TNF-alpha-induced expression of CF6 in a dose-dependent manner. The activation of CF6 stimulated by TNF-alpha was suppressed by ROS in a dose-dependent manner.
  
  
  CONCLUSIONS
  TNF-alpha-induced enhancement of the gene expression and release of CF6 is mediated by activation of NF-kappaB signaling pathway. ROS can inhibit the activation of IKK, block NF-kappaB signaling pathway and inhibit the expression of CF6, which may be the mechanism underlying the action of TZDs on hypertension.
authors.affiliation: Department of Cardiology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
authors.forename: Ze-bing
authors.initials: ZB
authors.lastname: Ye
authors.forename: Zhi-liang
authors.initials: ZL
authors.lastname: Li
authors.forename: Shu-dong
authors.initials: SD
authors.lastname: Song
authors.forename: Di-guang
authors.initials: DG
authors.lastname: Pan
authors.forename: Qiang
authors.initials: Q
authors.lastname: Fu
authors.forename: Ying-feng
authors.initials: YF
authors.lastname: Liu
mesh_terms: D002478:Cells, Cultured; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007150:Immunohistochemistry; D025261:Mitochondrial Proton-Translocating ATPases / Q000096:biosynthesis*; D016328:NF-kappa B / Q000096:biosynthesis*; D010086:Oxidative Phosphorylation Coupling Factors / Q000096:biosynthesis*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*; D014471:Umbilical Veins / Q000166:cytology
chemical_list: D007004:Hypoglycemic Agents; D016328:NF-kappa B; D010086:Oxidative Phosphorylation Coupling Factors; D045162:Thiazolidinediones; D014409:Tumor Necrosis Factor-alpha; D000077154:Rosiglitazone; C000628217:F(6) ATPase; D025261:Mitochondrial Proton-Translocating ATPases